Journal article
Gene Signatures in Stage II Colon Cancer: A Clinical Review
Current colorectal cancer reports, Vol.8(3), pp.225-231
09/2012
DOI: 10.1007/s11888-012-0132-7
PMCID: PMC3446849
PMID: 23002390
Abstract
Understanding the biology of cancer is the key to understanding its behavior. Stage II colon cancers represent a unique treatment challenge for medical oncologists because they contain a very heterogeneous group of tumors with a wide range of recurrence risks after resection. Defining these differences in biology can help to explain differences in disease behavior. To this end, gene signatures have been developed to define various prognostic groups beyond the clinicopathologic features alone. Adjuvant chemotherapy for stage II colon cancers as a group has not shown survival advantage in clinical trials. Future research to develop gene signatures to predict a group that will benefit from adjuvant chemotherapy will be helpful in the clinical decision-making process. The purpose of this review is to present the prognostic gene signatures currently available for use, those in development, and their utility in stratifying recurrence risk in stage II colon cancer patients.
Details
- Title: Subtitle
- Gene Signatures in Stage II Colon Cancer: A Clinical Review
- Creators
- Saima Sharif - Allegheny Cancer Center at Allegheny General Hospital Pittsburgh PA USAMichael O’Connell - National Surgical Adjuvant Breast and Bowel Project (NSABP) Four Allegheny Center Suite 587 Pittsburgh PA 15212 USA
- Resource Type
- Journal article
- Publication Details
- Current colorectal cancer reports, Vol.8(3), pp.225-231
- DOI
- 10.1007/s11888-012-0132-7
- PMID
- 23002390
- PMCID
- PMC3446849
- NLM abbreviation
- Curr Colorectal Cancer Rep
- ISSN
- 1556-3790
- eISSN
- 1556-3804
- Publisher
- Current Science Inc
- Language
- English
- Date published
- 09/2012
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094323602771
Metrics
14 Record Views